• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞-胆管细胞癌联合:一项临床病理研究。

Combined hepatocellular-cholangiocarcinoma: a clinicopathological study.

作者信息

Ng I O, Shek T W, Nicholls J, Ma L T

机构信息

Department of Pathology, the University of Hong Kong, Queen Mary Hospital, Pokfulam.

出版信息

J Gastroenterol Hepatol. 1998 Jan;13(1):34-40. doi: 10.1111/j.1440-1746.1998.tb00542.x.

DOI:10.1111/j.1440-1746.1998.tb00542.x
PMID:9737569
Abstract

Combined hepatocellular-cholangiocarcinoma (HCC-CC) is an uncommon form of primary liver cancer having features of both hepatocellular and biliary epithelial differentiation. We reviewed 21 cases of this tumour diagnosed between 1972 and 1996 (patient age range 16-79 years; mean patient age 49.7 years; 18 male and three female patients). Histologically, the majority (n = 18) of tumours were 'mixed' tumours, in which areas of hepatocellular and biliary epithelial differentiation were intimately mixed within the same tumours. Two patients had separate tumours in which discrete nodules of HCC and CC occurred in the same livers. One patient had a 'fibrolamellar' tumour that histologically simulated the fibrolamellar variant of HCC, but some of the tumour cells were mucin-producing cells. Of the 21 cases, mucin was demonstrable in 16 and, in the few mucin-negative tumours, electron microscopic studies confirmed the presence of the dual differentiation. The tumours frequently exhibited an invasive character with frequent venous permeation, direct invasion into adjacent liver parenchyma and tumour microsatellite formation, similar to that of ordinary HCC. Histological evidence of cirrhosis or chronic hepatitis was present in 77.8% of patients and 75% of patients were hepatitis B surface antigen positive. Raised serum alpha-fetoprotein (AFP) levels (above 300 ng/mL) were present in 61.5% of patients and AFP was detected immunohistochemically in 55% of tumours. The overall survival times of patients with HCC-CC were short. In conclusion, HCC-CC showed clinical and pathological features more akin to those of ordinary HCC than to CC.

摘要

肝内胆管癌合并肝细胞癌(HCC-CC)是一种罕见的原发性肝癌,具有肝细胞和胆管上皮分化的特征。我们回顾了1972年至1996年间诊断的21例该肿瘤患者(患者年龄范围为16 - 79岁;平均年龄49.7岁;18例男性患者和3例女性患者)。组织学上,大多数(n = 18)肿瘤为“混合型”肿瘤,其中肝细胞和胆管上皮分化区域在同一肿瘤内紧密混合。2例患者有独立的肿瘤,在同一肝脏中出现离散的HCC和CC结节。1例患者有一个“纤维板层样”肿瘤,组织学上模拟了HCC的纤维板层样变体,但部分肿瘤细胞为黏液分泌细胞。在这21例病例中,16例可检测到黏液,在少数黏液阴性的肿瘤中,电镜研究证实了双重分化的存在。这些肿瘤常表现出侵袭性,频繁发生静脉浸润、直接侵犯相邻肝实质和形成肿瘤微卫星,类似于普通HCC。77.8%的患者有肝硬化或慢性肝炎的组织学证据,75%的患者乙肝表面抗原阳性。61.5%的患者血清甲胎蛋白(AFP)水平升高(高于300 ng/mL),55%的肿瘤免疫组化检测到AFP。HCC-CC患者的总生存时间较短。总之,HCC-CC的临床和病理特征更类似于普通HCC而非CC。

相似文献

1
Combined hepatocellular-cholangiocarcinoma: a clinicopathological study.肝细胞-胆管细胞癌联合:一项临床病理研究。
J Gastroenterol Hepatol. 1998 Jan;13(1):34-40. doi: 10.1111/j.1440-1746.1998.tb00542.x.
2
Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases.肝细胞癌合并胆管癌:26例手术切除病例的临床病理研究
Jpn J Clin Oncol. 2003 Jun;33(6):283-7. doi: 10.1093/jjco/hyg056.
3
Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma.切除的肝细胞癌合并胆管癌的艾伦C型分类的临床和病理特征:与肝细胞癌和胆管细胞癌的比较研究
J Gastrointest Surg. 2006 Jul-Aug;10(7):987-98. doi: 10.1016/j.gassur.2006.01.018.
4
Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.肝细胞癌合并胆管癌与肝细胞癌及肝内胆管癌的比较。
Surg Today. 2006;36(10):892-7. doi: 10.1007/s00595-006-3276-8.
5
Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.15例肝细胞癌合并胆管癌患者的临床病理特征
Hepatobiliary Pancreat Dis Int. 2007 Apr;6(2):161-5.
6
Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection.肝移植和切除术后肝细胞癌-胆管癌合并症的长期预后
Liver Transpl. 2017 Mar;23(3):330-341. doi: 10.1002/lt.24711.
7
Combined hepatocellular and cholangiocarcinoma: correlation between CT findings and clinicopathological features.肝细胞癌与胆管癌混合型:CT表现与临床病理特征的相关性
J Comput Assist Tomogr. 1997 Jan-Feb;21(1):52-8. doi: 10.1097/00004728-199701000-00011.
8
Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers.与其他肝癌相比,肝细胞癌-胆管细胞癌混合癌的临床和病理特征。
J Gastroenterol Hepatol. 2019 Jun;34(6):1074-1080. doi: 10.1111/jgh.14547. Epub 2018 Dec 16.
9
Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features.肝细胞癌与胆管癌混合型:根据细胞角蛋白表达提出的标准及临床病理特征分析
Hum Pathol. 1995 Sep;26(9):956-64. doi: 10.1016/0046-8177(95)90084-5.
10
Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population.中国人肝细胞癌和胆管细胞癌合并癌与肝细胞癌和肝内胆管细胞癌的影像学特征比较。
Clin Radiol. 2019 May;74(5):407.e1-407.e10. doi: 10.1016/j.crad.2019.01.016. Epub 2019 Feb 21.

引用本文的文献

1
Establishment of a prognostic nomogram and risk stratification system for patients with combined hepatocellular-cholangiocarcinoma.建立肝细胞-胆管癌患者的预后列线图和风险分层系统。
Sci Rep. 2025 May 14;15(1):16726. doi: 10.1038/s41598-025-01817-2.
2
Morphomolecular Pathology and Genomic Insights into the Cells of Origin of Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma.胆管癌和肝细胞胆管癌起源细胞的形态分子病理学与基因组学见解
Am J Pathol. 2025 Mar;195(3):345-361. doi: 10.1016/j.ajpath.2024.08.014. Epub 2024 Sep 26.
3
Surgical Strategies for Combined Hepatocellular-Cholangiocarcinoma (cHCC-CC).
肝细胞-胆管细胞癌(cHCC-CC)的手术策略
Cancers (Basel). 2023 Jan 26;15(3):774. doi: 10.3390/cancers15030774.
4
Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update.肝细胞癌-胆管癌合并症的病理学:最新进展
Cancers (Basel). 2023 Jan 13;15(2):494. doi: 10.3390/cancers15020494.
5
Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study.根治性切除术后肝细胞癌-胆管细胞癌混合癌患者的预后分析:一项回顾性多中心队列研究。
World J Gastroenterol. 2022 Nov 7;28(41):5968-5981. doi: 10.3748/wjg.v28.i41.5968.
6
Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.酪氨酸激酶抑制剂和铂类化疗对不可切除或转移性肝内胆管癌患者的全身治疗
Liver Cancer. 2022 Jun 14;11(5):460-473. doi: 10.1159/000525488. eCollection 2022 Sep.
7
Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis.联合肝细胞癌和胆管细胞癌与肝细胞癌和胆管细胞癌患者术后临床特征和结局的比较:倾向评分匹配分析。
BMC Gastroenterol. 2021 Jan 7;21(1):20. doi: 10.1186/s12876-020-01586-4.
8
Elevated neutrophil-to-lymphocyte ratio and predominance of intrahepatic cholangiocarcinoma prediction of poor hepatectomy outcomes in patients with combined hepatocellular-cholangiocarcinoma.中性粒细胞与淋巴细胞比值升高和肝内胆管细胞癌为主型与合并肝细胞癌-胆管细胞癌患者肝切除术后不良结局相关。
PLoS One. 2020 Dec 11;15(12):e0240791. doi: 10.1371/journal.pone.0240791. eCollection 2020.
9
New insights into the pathophysiology and clinical care of rare primary liver cancers.罕见原发性肝癌病理生理学与临床护理的新见解。
JHEP Rep. 2020 Aug 24;3(1):100174. doi: 10.1016/j.jhepr.2020.100174. eCollection 2021 Feb.
10
Long-term outcome and prognostic factors of combined hepatocellular carcinoma and cholangiocarcinoma after curative resection.根治性切除术后肝细胞癌合并胆管癌的长期预后及预后因素
Gastroenterol Rep (Oxf). 2020 Mar 13;8(2):134-142. doi: 10.1093/gastro/goaa003. eCollection 2020 Apr.